A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection-Reference-Cited by-同舟云学术

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

Published:2011-09 Issue:9 Volume:22 Page:2042-2048
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wong R.,Cunningham D.,Barbachano Y.,Saffery C.,Valle J.,Hickish T.,Mudan S.,Brown G.,Khan A.,Wotherspoon A.,Strimpakos A.S.,Thomas J.,Compton S.,Chua Y.J.,Chau I.

Funder

National Institute for Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/9/2042/13785284/mdq714.pdf

Reference33 articles.

1. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET);Fernandez;Ann Surg,2004

2. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial;Nordlinger;Lancet,2008

3. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741;Sanoff;J Clin Oncol,2008